Survodutide vs Tesamorelin
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Survodutide
Survodutide (BI 456906) is a dual GLP-1/glucagon receptor agonist developed by Boehringer Ingelheim in partnership with Zealand Pharma. It is being developed primarily for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) and obesity. Survodutide's glucagon receptor activation promotes hepatic fat mobilization, making it uniquely suited for liver-related metabolic conditions.
Full details →Tesamorelin
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It is FDA-approved under the brand name Egrifta for reducing excess abdominal fat in HIV-infected patients with lipodystrophy.
Full details →Side-by-Side Comparison
| Aspect | Survodutide | Tesamorelin |
|---|---|---|
| Mechanism | Survodutide activates both GLP-1 and glucagon receptors. The GLP-1 component provides appetite suppression, glucose-dependent insulin secretion, and delayed gastric emptying. The glucagon component drives hepatic fat oxidation, increases energy expenditure, and promotes lipolysis. This dual mechanism is particularly effective for MASH, where hepatic fat accumulation is the core pathology. Unlike tirzepatide (which targets GIP/GLP-1), survodutide targets glucagon/GLP-1 — a different receptor combination optimized for liver and metabolic outcomes. | Stimulates the pituitary gland to produce and release growth hormone by binding to GHRH receptors. Increases IGF-1 levels which promotes lipolysis and reduces visceral adipose tissue. |
| Typical Dosage | Phase 2 MASH trial: escalated to 2.4 mg, 4.8 mg, or 6.0 mg weekly. Phase 2b obesity trial: up to 6.0 mg weekly. Dose escalation over 16-20 weeks to manage GI tolerability. Final approved dosing not yet established — Phase 3 trials ongoing. | FDA-approved dose: 2mg administered subcutaneously once daily. Research protocols may use various dosing schedules. |
| Administration | Subcutaneous injection, once weekly. Phase 3 trials use pre-filled pens. Not yet commercially available. Phase 3 results expected 2026-2027. | Subcutaneous injection into the abdomen. Rotate injection sites. Best administered at the same time daily, preferably in the evening. |
| Side Effects | Phase 2 data: nausea, vomiting, diarrhea (dose-dependent, generally transient). Reduced appetite. Transient increases in heart rate. The GI side effect profile appears similar to other GLP-1 agonists. | Common side effects include injection site reactions (erythema, pruritus), joint pain, peripheral edema, and muscle pain. May cause elevated blood glucose. |
| Best For |
Key Differences
Unique to Survodutide:
Unique to Tesamorelin:
Detailed Analysis
Commonalities
Survodutide and Tesamorelin are used for different purposes and have limited overlap in their applications.
Which Should You Choose?
Choose Survodutide for Weight Loss, Liver Health. Choose Tesamorelin for Muscle Growth, Fat Loss.
Ready to Learn More?
Looking for trusted sources?